Dr. Alpna Hansraj Seth Appointed Independent Director of Dr. Reddy’s Laboratories

Dr. Alpna Hansraj Seth has been appointed as an Additional Independent Director of Dr. Reddy’s Laboratories Limited, for a term of five consecutive years, effective from September 19, 2023. Her appointment is approved by the Board of Directors of the Company.

Dr. Seth served as the President and Chief Executive Officer of Nura Bio Inc., a neurology pharmaceutical company for 3 years until October 2022. Prior to this, She was the COO of Vir Bio Inc. and between 1998 and 2017 served as a senior executive at Biogen Inc., a leading global biopharmaceutical company. Early in her career at Biogen, she led oncology R&D which culminated in a merger with Idec Pharma to form Biogen Idec.  She brings corporate governance and strategic oversight experience as a member of the Board of Directors of large publicly listed multinationals and VC-funded private biotech companies. Dr. Seth currently serves as an independent Director on the boards of three public (NASDAQ-listed) companies- Seagen, Bio-Techne and Keros Therapeutics.  She received a Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts’ Medical School and conducted her post-doctoral research at Harvard University in immunology and structural biology, both as a Howard Hughes Medical Institute Fellow. She is also a graduate of Harvard Business School’s Advanced Management Program.